$465.67
Value $251B
AmgenvsBio-Techne
AMGN and TECH stock compared: price, dividend, valuation and results, from SEC filings.
-0.30%
$72.80
Value $11.4B
Amgen (AMGN) has a market value of $251B and Bio-Techne (TECH) $11.4B. Over the last year, with dividends, AMGN moved +42.3% and TECH +19.4%. The P/E is 26.7 for AMGN and 66.5 for TECH. Dividend yield: AMGN 2.13%, TECH 0.44%.
At a glance
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
AMGN$251B
TECH$11.4B
AMGN is 22 times TECH
Revenue, 12 months
AMGN$38.9B
TECH$1.2B
AMGN is 32 times TECH
Net income, 12 months
AMGN$9.4B
TECH$172M
AMGN is 55 times TECH
Operating margin
AMGN32.4%
TECH19.6%
12.8 points apart
ROIC
AMGN16.2%
TECH7.7%
8.5 points apart
P/E
AMGN26.7
TECH66.5
TECH is 2.5 times AMGN
Dividend yield
AMGN2.1%
TECH0.4%
1.7 points apart
5-year return
AMGN+157.4%
TECH-40.9%
198.3 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
The price over time
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
AMGN+157.4%
TECH-40.9%
| Period | AMGNWith dividends | TECHWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +42.3%Price +38.5% | +19.4%Price +18.6% |
| 3 years since November 13, 2023 | +91.0%+24.1% a yearPrice +74.6% | +29.5%+9.0% a yearPrice +27.5% |
| 5 years since November 12, 2021 | +157.4%+20.8% a yearPrice +120.3% | -40.9%-10.0% a yearPrice -42.3% |
| 10 years since November 15, 2016 | +323.6%+15.5% a yearPrice +216.7% | +190.5%+11.3% a yearPrice +174.4% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
Every figure
As on each company's page. A description, not a recommendation: no one figure says which is better.
AMGNAmgenTECHBio-Techne
Valuation
AMGNTECH| Price | $465.67 | $72.80 |
|---|---|---|
| Market value | $251B | $11.4B |
| Enterprise value (EV) | $292B | $11.5B |
| P/E | 26.7 | 66.5 |
| P/E, 5-year median | 23.0 | 56.6 |
| P/B | 17.5 | 5.3 |
| EV/EBIT | 23.1 | 47.7 |
| Free cash flow yield | 3.8% | 2.7% |
Results and growth
AMGNTECH| Revenue, 12 months | $38.9B | $1.2B |
|---|---|---|
| Net income, 12 months | $9.4B | $172M |
| Free cash flow, 12 months | $9.6B | $308M |
| Earnings per share, 12 months | $17.25 | $1.09 |
| Revenue growth, year on year | 10.0% | -0.4% |
| Revenue growth a year, past | +7.6%over 5 years | +5.5%over 5 years |
| EPS growth a year, past | +2.9%over 5 years | +5.9%over 5 years |
Margins and returns on capital
AMGNTECH| Gross margin | 70.9% | 65.8% |
|---|---|---|
| Operating margin | 32.4% | 19.6% |
| Net margin | 24.1% | 14.0% |
| ROIC | 16.2% | 7.7% |
| ROE | 87.8% | 8.3% |
Balance sheet
AMGNTECH| Cash | $13.2B | $350M |
|---|---|---|
| Total debt | $54.0B | $486M |
| Net debt / EBITDA | 2.3 | 0.2 |
| Interest cover | 4.8× | 27.2× |
Dividends and buybacks
AMGNTECH| Dividend yield | 2.1% | 0.4% |
|---|---|---|
| Dividend per share, 12 months | $9.94 | $0.32 |
| Dividend growth a year, past | +8.1%over 5 years | +0.0%over 5 years |
| Buyback yield | – | 0.4% |
| Shareholder yield | 2.1% | 0.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
Which is bigger, Amgen or Bio-Techne?
By market value, Amgen ($251B) is about 22.0 times Bio-Techne ($11.4B), at today's prices.
How did AMGN and TECH stock do over the last 10 years?
Since November 15, 2016, AMGN's price moved +216.7% and TECH's +174.4%. With dividends: AMGN +323.6% (+15.5% a year), TECH +190.5% (+11.3% a year). Past returns do not predict future ones.
Which pays the higher dividend, AMGN or TECH?
The dividend yield at today's price is 2.13% for Amgen and 0.44% for Bio-Techne. Over the last twelve months they paid $9.94 and $0.32 per share.
What is the P/E of AMGN and TECH?
At today's price, the P/E is 26.7 for AMGN and 66.5 for TECH. The median of the last five years was 23.0 and 56.6, which shows where each stands against its own past.
Which has the higher profit margins, Amgen or Bio-Techne?
Over the last twelve months, the net margin was 24.1% for Amgen and 14.0% for Bio-Techne, and the operating margin 32.4% and 19.6%. Revenue was $38.9B and $1.2B.
Which is the better investment, Amgen or Bio-Techne?
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
Other comparisons
With each of the two, and with the largest in its sector.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.
Descriptive data from SEC filings and market prices.